-
Australia's Steve Smith ruled out of third Ashes Test
-
Khawaja grabs lifeline as Australia reach 94-2 in 3rd Ashes Test
-
Undefeated boxing great Crawford announces retirement
-
Trump says orders blockade of 'sanctioned' Venezuela oil tankers
-
UK experiences sunniest year on record
-
Australia holds first funeral for Bondi Beach attack victims
-
FIFA announces $60 World Cup tickets after pricing backlash
-
Maresca relishes support of Chelsea fans after difficult week
-
Players pay tribute to Bondi victims at Ashes Test
-
Costa Rican president survives second Congress immunity vote
-
Married couple lauded for effort to thwart Bondi Beach shootings
-
Australia holds first funerals for Bondi Beach attack victims
-
Trump has 'alcoholic's personality,' chief of staff says in bombshell interview
-
Rob Reiner killing: son to be charged with double murder
-
Chelsea battle into League Cup semis to ease pressure on Maresca
-
Netflix boss promises Warner Bros films would still be seen in cinemas
-
Grok spews misinformation about deadly Australia shooting
-
Stocks mostly retreat on US jobs, oil drops on Ukraine hopes
-
Artificial snow woes for Milan-Cortina Winter Olympics organisers
-
Trump imposes full travel bans on seven more countries, Palestinians
-
New Chile leader calls for end to Maduro 'dictatorship'
-
Shiffrin extends slalom domination with Courchevel win
-
Doctor sentenced for supplying ketamine to 'Friends' star Perry
-
Tepid 2026 outlook dents Pfizer shares
-
Rob Reiner murder: son not medically cleared for court
-
FIFA announces $60 World Cup tickets for 'loyal fans'
-
Dembele and Bonmati scoop FIFA Best awards
-
Shiffrin dominates first run in Courchevel slalom
-
EU weakens 2035 combustion-engine ban to boost car industry
-
Arctic sees unprecedented heat as climate impacts cascade
-
French lawmakers adopt social security budget, suspend pension reform
-
Afrikaners mark pilgrimage day, resonating with their US backers
-
Lawmakers grill Trump officials on US alleged drug boat strikes
-
Hamraoui loses case against PSG over lack of support after attack
-
Trump - a year of ruling by executive order
-
Iran refusing to allow independent medical examination of Nobel winner: family
-
Brazil megacity Sao Paulo struck by fresh water crisis
-
Australia's Green becomes most expensive overseas buy in IPL history
-
VW stops production at German site for first time
-
Man City star Doku sidelined until new year
-
Rome's new Colosseum station reveals ancient treasures
-
EU eases 2035 combustion-engine ban to boost car industry
-
'Immense' collection of dinosaur footprints found in Italy
-
US unemployment rises further, hovering at highest since 2021
-
Senators grill Trump officials on US alleged drug boat strikes
-
Filmmaker Rob Reiner's son to be formally charged with parents' murder
-
Shift in battle to tackle teens trapped in Marseille drug 'slavery'
-
Stocks retreat on US jobs, oil drops on Ukraine hopes
-
Manchester United 'wanted me to leave', claims Fernandes
-
Serbian President blames 'witch hunt' for ditched Kushner hotel plan
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.

The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
H.Gonzales--AT